This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Elevance Health (ELV) Up 0% Since Last Earnings Report?
by Zacks Equity Research
Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cigna (CI) Q1 Earnings Surpass Estimates, Ups '23 EPS View
by Zacks Equity Research
Cigna's (CI) first-quarter 2023 results indicate a strong contribution to revenues from Evernorth Health Services and Cigna Healthcare businesses. Management currently expects adjusted EPS to be a minimum of $24.70 in 2023.
Acadia Healthcare (ACHC) Q1 Earnings Beat on Higher Patient Volumes
by Zacks Equity Research
Acadia Healthcare's (ACHC) Q1 results reflect higher revenue per patient day, partly offset by an elevated cost level. Management reaffirms its 2023 business guidance.
Teladoc Health (TDOC) Shares Up 5% Since Q1 Earnings Release
by Zacks Equity Research
Teladoc Health's (TDOC) Q1 results reflect solid chronic care product revenues and improving access fees and other revenues.
ELV vs. AMEH: Which Stock Is the Better Value Option?
by Zacks Equity Research
ELV vs. AMEH: Which Stock Is the Better Value Option?
AMN Healthcare (AMN) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
AMN Healthcare's (AMN) first-quarter results are likely to reflect soft demand across its segments.
Universal Health (UHS) Q1 Earnings Beat on Higher Admissions
by Zacks Equity Research
Universal Health's (UHS) Q1 results reflect strong performance in acute care and behavioral health segments. Meanwhile, the elevated expense level partially offsets the positives.
Humana (HUM) Q1 Earnings Beat on Growing Membership & Premiums
by Zacks Equity Research
Humana (HUM) expects adjusted EPS to be at least $28.25 in 2023, up from the previous guidance of $28 per share.
Centene (CNC) Q1 Earnings Miss Estimates, '23 EPS View Raised
by Zacks Equity Research
Centene's (CNC) first-quarter 2023 results grapple with higher operating expenses, partly offset by an expanding customer base. Management presently expects adjusted EPS to be at least $6.40 in 2023.
Elevance Health (ELV) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Elevance Health (ELV) is well positioned to outperform the market, as it exhibits above-average growth in financials.
HCA Healthcare (HCA) Beats on Q1 Earnings, Ups '23 EPS View
by Zacks Equity Research
HCA Healthcare's (HCA) first-quarter results gain from increased patient admissions. Management expects EPS within the $17.25-$18.55 band this year, higher than the previous view of $16.40-$17.60.
Elevance Health (ELV) Beats on Q1 Earnings, Hikes Profit View
by Zacks Equity Research
Elevance Health's (ELV) first-quarter results reflect growing premiums stemming from rate increases.
Elevance Health (ELV) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Elevance Health (ELV) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Elevance Health (ELV) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 2.16% and 2.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ELV or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. DOCS: Which Stock Is the Better Value Option?
Elevance Health (ELV) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Elevance Health's (ELV) first-quarter results are likely to reflect higher premiums, commercial and government sales figures and total expenses.
Elevance Health (ELV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Elevance Health (ELV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If You Invested $1000 in Elevance Health a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Establishment Labs Holdings Inc. (ESTA) Stock Jumps 6.1%: Will It Continue to Soar?
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
The Zacks Analyst Blog Highlights SAP, Elevance Health, Diageo, SLB and Charter Communications
by Zacks Equity Research
SAP, Elevance Health, Diageo, SLB and Charter Communications are included in this Analyst Blog.
Top Analyst Reports for SAP, Elevance Health & Diageo
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), Elevance Health, Inc. (ELV) and Diageo plc (DEO).
Here's Why Elevance Health (ELV) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Investors Should Retain Cigna (CI) Stock Now
by Zacks Equity Research
Cigna (CI) remains well-poised for growth on the back of continually growing premiums within its Cigna Healthcare unit. Solid cash-generating abilities also enable it to deploy capital.
Elevance (ELV) to Divest Life & Disability Business to StanCorp
by Zacks Equity Research
With the sale of the life and disability business, Elevance Health (ELV) is focusing on growing its more profitable operations.